These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31723838)

  • 1. AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells.
    Pearson S; Blance R; Somervaille TCP; Whetton AD; Pierce A
    Hemasphere; 2019 Jun; 3(3):e233. PubMed ID: 31723838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AXL Inhibition Represents a Novel Therapeutic Approach in
    Beitzen-Heineke A; Berenbrok N; Waizenegger J; Paesler S; Gensch V; Udonta F; Vargas Delgado ME; Engelmann J; Hoffmann F; Schafhausen P; von Amsberg G; Riecken K; Beumer N; Imbusch CD; Lorens J; Fischer T; Pantel K; Bokemeyer C; Ben-Batalla I; Loges S
    Hemasphere; 2021 Sep; 5(9):e630. PubMed ID: 34396051
    [No Abstract]   [Full Text] [Related]  

  • 5. Functional Consequences of Mutations in Myeloproliferative Neoplasms.
    Constantinescu SN; Vainchenker W; Levy G; Papadopoulos N
    Hemasphere; 2021 Jun; 5(6):e578. PubMed ID: 34095761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
    Ohyashiki JH; Yoneta M; Hisatomi H; Iwabuchi T; Umezu T; Ohyashiki K
    BMC Med Genet; 2012 Jan; 13():6. PubMed ID: 22251709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the Frequency of the
    Nasseri M; Keyfi F; Rahbarian R; Rajabian M; Abbaszadegan MR
    Rep Biochem Mol Biol; 2020 Jul; 9(2):188-192. PubMed ID: 33178868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
    Pasca S; Chifotides HT; Verstovsek S; Bose P
    Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications.
    Michiels JJ; Tevet M; Trifa A; Niculescu-Mizil E; Lupu A; Vladareanu AM; Bumbea H; Ilea A; Dobrea C; Georgescu D; Patrinoiu O; Popescu M; Murat M; Dragan C; Mihai F; Zurac S; Angelescu S; Iova A; Popa A; Gogulescu R; Popov V
    Maedica (Bucur); 2016 Mar; 11(1):5-25. PubMed ID: 28465746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.
    Stein BL; Williams DM; Rogers O; Isaacs MA; Spivak JL; Moliterno AR
    Exp Hematol; 2011 Jan; 39(1):95-101. PubMed ID: 20888389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
    Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
    Coltro G; Loscocco GG; Vannucchi AM
    Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
    Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
    Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
    Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
    Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.